AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Saturday 31 October 2026
News from the 24 hours to Saturday morning, 31 October 2026.
Tone of the day
+8.7strongly positive
+8.7
Relevant headlines78
Stories4
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on third-quarter results that beat forecasts, driven by cancer drug growth, alongside a $1.5bn annual savings plan and a confident pipeline outlook. Shares rose sharply and lifted the FTSE 100, with minor negatives from a halted trial and dropped early-stage programmes.
What drove it
- Q3 earnings beat
- savings and restructuring plan
- pipeline outlook
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
| Tue 27 Oct | +9.2 | 35 |
| Wed 28 Oct | +7.5 | 33 |
| Thu 29 Oct | +2.8 | 13 |
| Fri 30 Oct | +6.3 | 13 |
| Sat 31 Oct | +8.7 | 78 |
4 stories · 78 headlines · strongest first
Pharma and healthcare on 31 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca Q3 results and $1.5bn savings plan +7.059 headlines today · AstraZeneca reported 7% Q3 revenue growth, kept guidance, and launched a $1.5bn savings plan funding a $2bn pipeline investment; shares rose sharply. | ||
| +10.0 | Shares at multi-month high on chief executive's large pipeline potential claim | |
| +10.0 | Sharp share price rise after results | |
| +10.0 | Confident chief executive and rising shares | |
| +10.0 | Large potential from upcoming trial data, shares near breakout | |
| +10.0 | Sharp profit rise and cost savings programme | |
| +10.0 | Shares rallied on earnings beat and cancer drug growth | |
| +10.0 | Profit lifted by leading cancer medicines | |
| +10.0 | Long growth outlook backed by pipeline and approvals | |
| +10.0 | Earnings call points to strong cancer drug sales growth | |
| +10.0 | Earnings beat driven by cancer drug sales | |
| +10.0 | Strong share gain despite capped restructuring spend | |
| +10.0 | Sales and profit beat forecasts, shares up | |
| +10.0 | Shares climbed strongly on the day | |
| +9.2 | Record margin viewed as encouraging for next year | |
| +9.2 | Shares leap as pipeline investment begins | |
| +9.2 | Higher profits and savings plan | |
| +9.2 | Investment case strengthened by better-than-expected results | |
| +9.2 | Valuation commentary sees upside after strong quarter and pipeline progress | |
| +9.2 | Savings target and results ahead of forecasts | |
| +9.2 | Bank analyst keeps positive rating, praises pipeline activity | |
| +8.3 | Analyst commentary optimistic on potential major drugs | |
| +8.3 | Earnings call summary, generally positive tone | |
| +8.3 | Brokers view profit beat favourably, shares gain | |
| +8.3 | Revenue up and full-year guidance reaffirmed | |
| +8.3 | Strong year-to-date beat, guidance unchanged | |
| +8.3 | Higher adjusted earnings and revenue, outlook kept | |
| +8.3 | Strong drug sales and pipeline value offset by restructuring cost | |
| +8.3 | Broker positive recommendation | |
| +8.3 | Broker maintains positive rating | |
| +7.5 | Savings plan with workforce kept stable | |
| +7.5 | Multi-year efficiency programme aimed at funding late-stage development | |
| +7.5 | Revenue growth from cancer offsets decline of one drug | |
| +6.7 | Overhaul aimed at lowering annual costs | |
| +6.7 | Savings programme to finance drug development | |
| +6.7 | Annual cost savings planned to support pipeline | |
| +6.7 | Savings to be redirected into growth | |
| +6.7 | Investment into drug pipeline begins | |
| +6.7 | Savings plan announced alongside quarterly results | |
| +6.7 | Finance chief discusses results and pipeline outlook | |
| +6.7 | Solid quarterly figures | |
| +6.7 | Overhaul aimed at lowering annual costs | |
| +6.7 | Savings freed up for new medicines | |
| +6.7 | Full-year profit outlook maintained | |
| −5.8 | Late-stage trial halted due to disappointing expected efficacy | |
| +5.8 | Official nine-month and quarterly results release | |
| +5.8 | Reorganisation intended to fund pipeline | |
| +5.0 | Revenue rise noted at market open | |
| +5.0 | Key metrics compared with analyst expectations | |
| +5.0 | Ambitious growth target but share price had stalled | |
| +5.0 | Finance chief interview on AI, results and restructuring | |
| +4.2 | Restructuring spend announced for drug pipeline | |
| +4.2 | Brief roundup of results among several firms | |
| +4.2 | Guidance held despite pressure from generics | |
| +4.2 | Restructuring will not reduce overall headcount | |
| −3.3 | Early-stage prostate cancer programmes dropped | |
| −3.3 | Reorganisation may bring research cuts and trials moved abroad | |
| +2.5 | Newsletter roundup mentioning its cost cutting | |
| +1.7 | Transcript of results call, factual | |
| 0.0 | Notice that results call is under way | |
| FTSE 100 rises on AstraZeneca +8.415 headlines today · Market reports say gains in AstraZeneca shares supported the FTSE 100, which posted a gain for the month. | ||
| +10.0 | Shares surged on results, topping index risers | |
| +9.2 | Duplicate market report of its share jump | |
| +9.2 | Shares jumped after third-quarter figures | |
| +9.2 | Index higher on impressive results | |
| +9.2 | Index gain led by large rise in the company's shares | |
| +9.2 | French version of index report highlighting its share jump | |
| +8.3 | Index outperformance driven by its shares | |
| +8.3 | Its shares helped lift the London index | |
| +8.3 | Its rise offsets bank weakness in index | |
| +8.3 | Shares up on results at the open | |
| +8.3 | Shares higher after results, supporting index | |
| +7.5 | It holds up the index amid tech weakness | |
| +7.5 | Its rally helped index rise | |
| +7.5 | Shares rallying and lifting midday index | |
| +6.7 | Its gains helped support the index | |
| AstraZeneca CEO and CFO on cancer vaccines, GLP-1 pill and Oracle partnership +4.43 headlines today · Executives discussed cancer vaccine development, a GLP-1 pill and the Oracle AI partnership. | ||
| +5.8 | Obesity pill in development broadens future product range | |
| +5.8 | Chief executive discusses vaccines and AI partnership | |
| +1.7 | Cancer vaccine work to stay in-house for now | |
| Enhertu wins Prix Galien award +7.51 headline today · Enhertu was named winner of Best Biotechnology Product at the International Prix Galien in 2026. | ||
| +7.5 | Its cancer product won a major industry award | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.